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Abstract Swiss 3T3 cell lines were constructed co-expressing
receptor activity modifying protein (RAMP) 1 with the calcitonin
receptor-like receptor (CRLR), and showed 125I-calcitonin-gene-
related peptide (CGRP) 1 binding indicative of a type I CGRP
receptor. Application of CGRP1 led to an increase in cAMP,
which in 2/5 cell lines was augmented following pertussis toxin
(PTX) pre-treatment. In Xenopus oocytes, expression of
RAMP1, which potentiates an endogenous CGRP receptor, led
to constitutive activation of co-expressed GIRK potassium
channels. This potassium current was increased following CGRP
application or co-expression of CRLR, but decreased by PTX or
co-expression of transducin. We conclude that the CGRP
receptor can signal to both PTX sensitive and insensitive G
proteins.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The calcitonin-gene-related peptides (CGRP1 and CGRP2)
are 37 amino-acid neuropeptides that di¡er by three amino
acids and are members of a larger family that also contains
adrenomedullin, amylin and calcitonin. In addition to its ac-
tivity in the cardiovascular system, where it is a potent vaso-
dilator, CGRP also mediates anti-in£ammatory and neurotro-
phic e¡ects [1]. In a variety of cell lines and tissues CGRP
application leads to an increase in intracellular cAMP [2^4],
e¡ects which are consistent with coupling to the heterotrimer-
ic G protein Gs. This is supported by the observation that
antiserum against the amino-terminal region of Gs alpha im-
munoprecipitated a signi¢cant fraction of soluble CGRP re-
ceptors prepared from the rat cerebellum [5]. There is also
evidence that the CGRP receptor can activate guanylate cy-
clase and phospholipase C, as well as calcium and potassium
channels [6^10]. In some instances these responses occur via
pertussis toxin (PTX)-sensitive mechanisms [9,10], suggesting
the involvement of heterotrimeric G proteins in the Gi and Go
family [8].
We have recently established that in transient expression
systems co-expression of the calcitonin receptor-like receptor
(CRLR) [11,12] with a second protein, which we have named
the receptor activity modifying protein (RAMP1), confers
novel cAMP responses to CGRP and high a⁄nity 125I-
CGRP1 binding [13]. We have now generated Swiss 3T3 cell
lines that stably express CRLR and RAMP1 and in this study
we report the characteristics of the CGRP receptor that re-
sults from this co-expression. In some cell lines cAMP re-
sponses to CGRP were potentiated by pre-treatment with
PTX, suggesting that the recombinant CGRP receptor may
signal through both Gi and Gs. This hypothesis was examined
in Xenopus laevis oocytes that can be manipulated to provide
a sensitive readout for receptor activation via PTX sensitive
and insensitive G proteins.
2. Materials and methods
2.1. Construction of cell lines co-expressing CRLR and RAMP1
Swiss 3T3 cells were chosen as hosts because they are robust, ad-
herent and showed no detectable cAMP responses to CGRP, calcito-
nin or adrenomedullin. Cells were maintained at 37‡C and 95% hu-
midity in Dulbecco’s modi¢ed Eagle’s medium (DMEM)
supplemented with 10% foetal calf serum and 2 mM glutamine. The
human sequences for RAMP1 and CRLR (modi¢ed to provide a
consensus Kozak sequence) [11] were cloned into the expression vec-
tors pCIN4 and -5, respectively, which contain IRES elements with
neomycin and hygromycin resistance genes downstream and in frame.
Cells were transfected with 5 Wg of linearised DNA (as a mixture of
both constructs) per T75 cm2 £ask of 80% con£uent cells using a
lipofectamine procedure (Life Technologies). Dual neomycin and hy-
gromycin selection was imposed and after a number of weeks individ-
ual colonies were isolated and subjected to dilution cloning prior to
expansion. At a free radioligand concentration of 1 nM (which is
approximately the Kd for 125I-CGRP1 at the human receptor [2]) we
were unable to distinguish between 125I-CGRP1 binding to the di¡er-
ent cell lines (data not shown) and chose to analyse the line that grew
fastest in culture.
2.2. Radioligand binding
SK-N-MC cells (which endogenously express CGRP1 receptors [3])
and CRLR/RAMP1 double stable Swiss 3T3 cell lines were pelleted
by centrifugation at 500Ug for 10 min at 4‡C and then homogenised
in bu¡er containing 50 mM HEPES-KOH, 1 mM EDTA, 100 WM
leupeptin, 25 Wg/ml bacitracin; pH 7.6. Immediately before the ¢rst
homogenisation 1 mM PMSF and 2 WM pepstatin A were added.
After centrifugation at 500Ug for 20 min the supernatant was re-
moved and centrifuged at 48 000Ug for 30 min. The ¢nal pellet was
resuspended in homogenisation bu¡er (without PMSF or pepstatin A)
and the protein content was measured.
Membranes (50 Wg) were incubated for 90 min at 25‡C in binding
bu¡er (50 mM HEPES-KOH, 10 mM MgCl2, 1 mM EDTA, pH 7.4)
which contained 30 pM 125I-CGRP1 (Amersham), with or without
competing ligand (3 pM to 10 WM), in a total volume of 200 Wl.
Incubation was terminated by rapid ¢ltration through GF/C ¢lters
soaked in 0.1% polyethylenimine using a Tomtek (Wallac) cell har-
vester. Competition binding data were analysed by non-linear regres-
sion using the computer program ‘Excel Robosage’ (Microsoft).
2.3. cAMP assay
Cells were washed with PBS and pre-incubated in DMEM contain-
ing 300 WM IBMX (Sigma) for 30 min at 37‡C. Human CGRP1
(1^1000 nM) was added for a further 30 min at 37‡C and the cells
washed with ice cold PBS. cAMP levels were determined using
Scintillation Proximity based Assays (SPA, Amersham).
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2.4. Oocytes
Adult female Xenopus laevis (Blades Biologicals) were anaesthetised
using 0.2% tricaine (3-aminobenzoic acid ethyl ester), killed and the
ovaries rapidly removed. Oocytes were then de-folliculated by colla-
genase digestion (Sigma type I, 1.5 mg/ml) in divalent cation-free OR2
solution (82.5 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 5 mM
HEPES; pH 7.5 at 25‡C). Single stage V and VI oocytes were trans-
fered to ND96 solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl2,
5 mM HEPES, 2.5 mM sodium pyruvate; pH 7.5 at 25‡C) which
contained 50 Wg/ml gentamycin and stored at 18‡C. Co-expression
of the G-protein regulated potassium channels GIRK1 (Kir 3.1 [14])
and GIRK4 (or CIR, Kir 3.4 [15]) (injected in equal amounts to
generate a heteromeric channel) was used to assay for activation of
PTX sensitive G proteins [16]. A high potassium solution (90K) con-
taining 90 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES
(pH 7.5 at 25‡C) was used in all GIRK experiments to increase po-
tassium current amplitude.
RAMP1, CRLR, GIRK1, GIRK4 (all in pcDNA3, Invitrogen) and
CFTR (in pBluescript, Stratagene) were linearised and transcribed to
RNA using T7 or T3 polymerase (Promega Wizard kit).
mPG(5P)pp(5P)GTP capped cRNA was injected into oocytes (20^50
ng per oocyte) and whole-cell currents were recorded using two-micro-
electrode voltage-clamp (GeneClamp Ampli¢er, Axon Instruments)
3^7 days post-RNA injection. Microelectrodes had a resistance of
0.5^2 M6 when ¢lled with 3 M KCl.
2.5. Chemicals
Human CGRP peptides, calcitonin and amylin were obtained from
Bachem; adrenomedullin (13^52) was from Peninsula Labs. and
CGRP1 was synthesised at GlaxoWellcome. All other chemicals
were of Analar grade and were obtained from Sigma.
3. Results
3.1. Characterisation of the CGRP receptor in Swiss 3T3 cells
co-expressing RAMP1 and CRLR
Five Swiss 3T3 cell lines were isolated that grew under neo-
mycin and hygromycin selection inferring expression of both
CRLR and RAMP1. Each cell line expressed high a⁄nity and
speci¢c 125I-CGRP1 binding sites, whereas there was no spe-
ci¢c binding of 125I-CGRP1 to native Swiss 3T3 cells. Some
Swiss 3T3 lines have been shown to express adrenomedullin
receptors [17] ; however, we were unable to detect speci¢c
ADM binding in the cell line we used (data not shown).
Fig. 1A shows the ability of CGRP, CGRP analogues, adre-
nomedullin, salmon calcitonin, amylin and calcitonin to
compete for 125I-CGRP1 binding to SK-N-MC cells and
to one of the Swiss 3T3 cell lines (number 5). The rank order
of potency was the same in each case: CGRP1s L-turn
derived CGRPsCGRP8ÿ37 = Pro-8 CGRP8ÿ37sAla-16
CGRP8ÿ37s adrenomedullin 13^52Eamylin/calcitonin. Ta-
ble 1 shows the pIC50 values that correspond to these curves.
These data are consistent with a type 1 CGRP receptor phar-
macology [2], as seen previously in transient expression sys-
tems [13].
In each Swiss 3T3 cell line application of CGRP1 (1^1000
nM) led to a small, dose-dependent increase in intracellular
cAMP, which reached a maximum value of about 20^50 pmol
cAMP per well at 1000 nM (Fig. 1B). Interestingly, cell lines
4 and 5 showed a signi¢cant increase in their intracellular
cAMP responses to CGRP1 following pre-treatment with
PTX (Fig. 2). This data could be explained if the CGRP
receptor couples to both Gi and Gs, which have opposing
actions on adenylate cyclase, and pre-treatment with PTX
relieves a Gi-mediated, CGRP-dependent inhibition of adeny-
late cyclase.
3.2. Constitutive coupling of the CGRP receptor via
PTX-sensitive G proteins to the GIRK1/4 heteromeric
potassium channel in Xenopus oocytes
A number of G-protein coupled receptors have been shown
to activate the inward recti¢er potassium channels GIRK1
and GIRK4 when co-expressed in oocytes from Xenopus laevis
(illustrated using the activity of adenosine on the adenosine
A1 receptor, see Fig. 2A, middle panel). This activation is
inhibited by pre-treatment with PTX and expression of G-
protein regulated potassium channels in oocytes has been
used extensively as a read-out for Gi-coupled receptors [16].
We therefore tested the hypothesis that the CGRP receptor
can signal through PTX-sensitive G proteins by co-expressing
RAMP1 (with or without CRLR) with GIRK1/4 in oocytes.
To facilitate the recording of inward potassium currents, the
extracellular solution was switched from ND96 (2 mM K) to
90K (90 mM K) solution prior to application of CGRP.
As shown in Fig. 2A (upper panel), in uninjected oocytes
switching from ND96 to 90K solution led to a small inward
shift in holding current (105.5 þ 29.7 nA at 360 mV, n = 7).
This was completely reversed by application of 1 mM BaCl2.
A similar shift in holding current was recorded in oocytes
expressing the adenosine A1 receptor plus GIRK1/4 (Fig.
2A, middle panel). However, in oocytes which expressed
RAMP1 plus GIRK1/4 a 3-fold larger shift in holding current
was recorded (305.6 þ 42.4 nA, n = 7) after switching to the
high potassium solution (Fig. 2A, lower panel). This current
was completely blocked by application of BaCl2 (1 mM) at a
concentration shown to selectively block inward recti¢er po-
tassium channels (Fig. 2B) [15]. Furthermore, the current-volt-
age curve for an oocyte expressing RAMP1 plus GIRK1/4
showed strong inward recti¢cation, consistent with activation
of the GIRK1/4 potassium channel (Fig. 2B). It therefore
appears that expression of RAMP1 in oocytes leads to acti-
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Table 1
Comparison of the CGRP receptor in SK-N-MC cells and CRLR/RAMP1 double stable cell lines using [125I]KCGRP
Compound SK-N-MC (pIC50 þ S.E.M.) CRLR/RAMP1 (pIC50 þ S.E.M.) n
CGRP 9.0 þ 0.1 9.0 þ 0.1 8
ADM 5.5 6.2 2
CGRP8ÿ37 7.9 þ 0.1 8.2 þ 0.3 3
Pro-8 CGRP8ÿ37 7.9 þ 0.2 8.2 þ 0.2 3
Ala-16 CGRP8ÿ37 6.9 þ 0.1 7.6 þ 0.03 3
BTD CGRP 8.2 þ 0.2 8.4 þ 0.02 3
Human calcitonin, salmon calcitonin and human amylin gave no signi¢cant displacement (n = 3 in each case).
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vation of the GIRK1/4 potassium channel, and to the gener-
ation of an inwardly rectifying potassium current.
Expression of RAMP1 in Xenopus oocytes potentiates the
endogenous oocyte CGRP receptor, such that a 100-fold in-
crease in CGRP responses are seen when the cystic ¢brosis
transmembrane regulator (CFTR) is used as a reporter [13]
(CFTR is responsive to changes in intracellular cAMP and its
activation is consistent with the CGRP receptor activating the
oocyte equivalent of Gs [18]). The most obvious explanation
for the RAMP1-induced stimulation of GIRK1/4 seen in this
study is therefore that RAMP1 facilitates the oocyte CGRP
receptor, and that this receptor activates the GIRK1/4 potas-
sium channels in a ligand-independent manner. We have per-
formed several experiments that address this hypothesis :
1. Application of 1 WM CGRP1 (in 90K solution) led to a
further increase in potassium current amplitude (10.6%
þ 3.3%, n = 7) supporting the view that RAMP1 expres-
sion activates GIRK1/4 through its actions on the en-
dogenous oocyte CGRP receptor (Fig. 2A, lower panel).
2. Increasing the number of functional CGRP receptors by
co-expression of CRLR with RAMP1 led to a signi¢-
cant increase in potassium current amplitude from
305.6 þ 42.4 nA (n = 12) to 501.5 þ 63.0 nA (n = 23,
P6 0.05) (Fig. 3A).
3. Pre-treatment of oocytes with PTX led to a large de-
crease in potassium current amplitude (59.4% þ 12.7%,
P6 0.05, n = 9, Fig. 3B, left panel) suggesting that acti-
vation of the potassium current is dependent upon sig-
nalling via G proteins of the Gi=o class.
4. Co-expression of transducin, which is known to bind G-
protein LQ subunits, led to marked (74.2 þ 5.5%, n = 5,
P6 0.05) reduction in potassium current amplitude (Fig.
3B, right panel).
While we cannot exclude the possibility that RAMP1 acti-
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Fig. 1. Characterisation of Swiss 3T3 cell lines expressing RAMP1 plus CRLR. A: Binding curves were constructed for a single Swiss 3T3 cell
line (number 5), and for native SK-N-MC cells using 30 pM 125I-CGRP1 as the radioligand, and various concentrations of competing ligand
(3 pM to 10 WM). Ligands used were CGRP1 (W), L-turn derived CGRP (b), CGRP8ÿ37 (O), Pro-8 CGRP8ÿ37 (F), Ala-16 CGRP8ÿ37 (a) and
adrenomedullin 13^52 (R). No competition was seen in either cell type with amylin or calcitonin. B: CGRP-dependent changes in cAMP pro-
duction were measured in the same Swiss 3T3 cell lines, in control conditions (left panel) and following pre-treatment with pertussis toxin (right
panel). A separate curve is shown for each individual cell line. Note the increase in CGRP-dependent cAMP production following PTX pre-
treatment in cell lines 4 and 5.
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vates an endogenous oocyte receptor other than that for
CGRP, and that this receptor shows constitutive activity,
two lines of evidence suggest that this is not the case. First,
RAMP1 has no signi¢cant activity on responses mediated by
endogenous oocyte adenosine, vasointestinal polypeptide or L-
adrenoreceptors suggesting that it acts speci¢cally on CRLR
and its oocyte equivalent [13]. Second, the increase in potas-
sium current seen following CGRP application or co-expres-
sion of CRLR is consistent with an action of RAMP1 on the
endogenous oocyte CGRP receptor. The most elegant demon-
stration that RAMP1 activates GIRK1/4 through constitutive
activation of the oocyte CGRP receptor awaits the develop-
ment of a CGRP receptor inverse agonist.
4. Discussion
When human embryonic kidney (HEK293T) cells are tran-
siently transfected with CRLR and RAMP1 they gain high
a⁄nity and speci¢c 125I-CGRP1 binding as well as novel
cAMP responses to CGRP1 [13]. We have extended these
studies by constructing Swiss 3T3 cell lines that stably express
RAMP1 and CRLR. All ¢ve cell lines tested (isolated and
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Fig. 3. The CGRP receptor couples to GIRK1/4 via a PTX-sensitive
pathway. A: Dot plot. The shift in holding current recorded on
switching from ND96 to 90K was measured for uninjected oocytes,
and for oocytes expressing RAMP1 alone, GIRK1/4 alone, RAMP1
plus GIRK1/4 and RAMP1, CRLR and GIRK1/4. Each circle rep-
resents an individual oocyte. B: E¡ects of pertussis toxin pre-treat-
ment (left panel) and transducin co-expression (right panel) on po-
tassium current amplitude (measured as described above). Both
treatments led to a reduction in potassium current amplitude sug-
gesting that, in oocytes expressing RAMP1, GIRK1/4 is constitu-
tively activated through Gi and the release of GLQ subunits.
Fig. 2. Expression of RAMP1 plus GIRK1/4 in Xenopus oocytes.
A: Current traces are shown for an uninjected oocyte (top panel),
an oocyte expressing the adenosine A1 receptor plus GIRK1/4 (mid-
dle panel) and for an oocyte expressing RAMP1 plus GIRK1/4
(lower panel). In each case, switching to high potassium (90K) solu-
tion led to an inward shift in holding current. Note the far larger
inward current recorded in an oocyte expressing RAMP1, and the
further increase in potassium current amplitude recorded following
application of 1 WM CGRP. B: Current-voltage curve (in 90K)
from an oocyte expressing RAMP1 plus GIRK1/4. Curves are
shown in ND96 (b), in 90K solution (a) and in 90K plus 1 mM
BaCl2 (E).
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expanded from individual clones) were found to have high
a⁄nity 125I-CGRP1 binding and a detailed analysis of one
clone showed that the pharmacology of the CGRP receptor
expressed is very similar to the native SK-N-MC cell CGRP
receptor.
We have demonstrated that the human and Xenopus CGRP
receptors can signal via PTX sensitive and insensitive G pro-
teins following expression in Swiss 3T3 cells or Xenopus oo-
cytes. It is interesting to note that the CGRP receptor in SK-
N-MC cells (which contain RAMP1 [13] and CRLR) may
also signal via opposing pathways, as CGRP-stimulated
cAMP production reaches a plateau at about 100 nM, with
higher concentrations of CGRP being less e¡ective (data not
shown). This e¡ect may be due to activation of Gi at high
CGRP concentrations. There is also good evidence that the
CGRP receptor can signal through Gi in native tissues, with
coupling to both calcium and potassium channels reported
[9,10]. Recently, Drissi and co-workers reported that in an
osteoblastic cell line CGRP can activate PLC-L1 and increase
intracellular Ca2 via the activation of Gq=11 [8]. However, at
least in Xenopus oocytes, we ¢nd no evidence for Gq-coupling
which would be detected as a transient chloride ion £ux
through endogenous calcium-activated chloride channels.
This may re£ect the fundamentally di¡erent cell background
in the two sets of experiments, or alternatively the receptor
characterised by Drissi et al. may be a di¡erent molecular
species to CRLR or the endogenous oocyte CGRP receptor.
With reference to the latter, it is notable that no cAMP re-
sponses to CGRP were observed in the osteoblastic cell line.
In many studies receptors have been reported to couple
through unforeseen and sometimes opposing pathways in re-
combinant systems, particularly if receptors are expressed at
arti¢cially high levels [19]. However, we do not appear to be
over-expressing the CGRP receptor in the present study since
our Swiss 3T3 cells show a comparable number of receptors to
those seen in non-transfected SK-N-MC cells (Bmax = 15 fmol
per mg membrane protein) and in native tissues [1,2]. The
degree to which the CGRP receptor would utilise di¡erent
signalling pathways would depend upon the equilibrium con-
stants inherent to interactions between receptor, ligand and G
protein, as well as to the available concentrations of the var-
ious components [20]. Further experiments are required to
elucidate the roles and relative importance of CGRP signal-
ling through these various pathways.
References
[1] Wimalawansa, S.J. (1996) Endocr. Rev. 17, 533^585.
[2] Poyner, D. (1995) Trends Pharmacol. Sci. 16, 424^428.
[3] Zimmermann, U., Fischer, J.A., Mu¡, R., Valen, F.V., Piechot,
G. and Jugen, S. (1990) Neurosci. Lett. 119, 195^198.
[4] Parsons, A.M. and Seybold, V.S. (1997) Synapse 26, 235^242.
[5] Chatterjee, T.K., Moy, J.A., Cai, J.J., Lee, H.C. and Fisher, R.A.
(1993) Mol. Pharmacol. 43, 167^175.
[6] Gray, D.W. and Marshall, I. (1992) Br. J. Pharmacol. 107, 691^
696.
[7] Laufer, R. and Changeux, J.P. (1989) J. Biol. Chem. 264, 2683^
2689.
[8] Drissi, H., Lasmoles, F., Le Mellay, V., Marie, P.J. and Lieber-
herr, M. (1998) J. Biol. Chem. 273, 20168^20174.
[9] Wiley, J.W., Gross, R.A. and MacDonald, R.L. (1992) J. Phys-
iol. 455, 367^381.
[10] Kim, D. (1991) P£uºgers Arch. 418, 338^345.
[11] Aiyar, N., Rand, K., Elshourbagy, N.A., Zeng, Z., Adamou,
J.E., Bergsma, D.J. and Li, Y. (1996) J. Biol. Chem. 271,
11325^11329.
[12] Fluhmann, B., Mu¡, R., Hunziker, W., Fischer, J.A. and Born,
W. (1995) Biochem. Biophys. Res. Commun. 206, 341^347.
[13] McLatchie, L.M., Fraser, N.J., Main, M.J., Wise, A., Brown, J.,
Thompson, N., Solari, R., Lee, M.G. and Foord, S.M. (1998)
Nature 393, 333^339.
[14] Kubo, Y., Reuveny, E., Slesinger, P.A., Jan, Y.H. and Jan, L.Y.
(1993) Nature 364, 802^806.
[15] Kaprivinsky, G., Gordon, E.A., Wickman, K., Velimirovic, B.,
Kaprivinsky, L. and Clapham, D.E. (1995) Nature 374, 135^141.
[16] Rimland, J.M., Seward, E.P., Humbert, Y., Ratti, E., Trist, D.G.
and North, R.A. (1996) Mol. Pharmacol. 49, 387^390.
[17] Withers, D.J., Coppock, H.A., Seu¡erlein, T., Smith, D.M.,
Bloom, S.R. and Rozengurt, E. (1996) FEBS Lett. 378, 83^87.
[18] Uezonzo, Y., Bradley, J., Min, C., McCarty, N.A., Quick, M.,
Riordan, J.R., Chavkin, C., Zinn, K., Lester, H.A. and David-
son, N. (1993) Recept. Channels 1, 233^241.
[19] Kenakin, T. (1997) Trends Pharmacol. Sci. 18, 456^464.
[20] Kenakin, T.P. and Morgan, P.H. (1989) Mol. Pharmacol. 35,
214^222.
FEBS 21256 14-12-98
M.J. Main et al./FEBS Letters 441 (1998) 6^1010
